ctDNA may predict outcomes with first-line, but not second-line immunotherapy for melanoma

Bottom Line: Baseline levels of circulating tumor DNA (ctDNA) predicted responses to first-line, but not second-line, immune checkpoint inhibition in patients with melanoma. Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: Elin Gray, PhD, an associate professor at Edith Cowan University in Australia […]